Taking everything into account, NAUT scores 2 out of 10 in our fundamental rating. NAUT was compared to 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for NAUT as it has an excellent financial health rating, but there are worries on the profitability. NAUT does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.26% | ||
| ROE | -37.14% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.01 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.95 | ||
| Quick Ratio | 14.95 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.95
+0.04 (+2.09%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.46 | ||
| P/tB | 1.46 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.26% | ||
| ROE | -37.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 72.3% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 14.95 | ||
| Quick Ratio | 14.95 | ||
| Altman-Z | 2.01 |
ChartMill assigns a fundamental rating of 2 / 10 to NAUT.
ChartMill assigns a valuation rating of 0 / 10 to NAUTILUS BIOTECHNOLOGY INC (NAUT). This can be considered as Overvalued.
NAUTILUS BIOTECHNOLOGY INC (NAUT) has a profitability rating of 0 / 10.